Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Monoclonal antibodies in sepsis and septic shock.

Literature DB >> 1571053

Monoclonal antibodies in sepsis and septic shock.

C J Hinds.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 1992 PMID： 1571053 PMCID： PMC1881179 DOI： 10.1136/bmj.304.6820.132

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

20 in total

1. Anonymised screening for HIV: first results.

Authors: T Delamothe
Journal: BMJ Date: 1991-05-25

2. Monoclonal antibodies to endotoxin. New allies against sepsis?

Authors: R C Bone
Journal: JAMA Date: 1991-08-28 Impact factor: 56.272

3. Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome.

Authors: C J Fisher; J Zimmerman; M B Khazaeli; T E Albertson; R P Dellinger; E A Panacek; G E Foulke; C Dating; C R Smith; A F LoBuglio
Journal: Crit Care Med Date: 1990-12 Impact factor: 7.598

4. Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5.

Authors: J D Baumgartner; D Heumann; T Calandra; M P Glauser
Journal: J Infect Dis Date: 1991-04 Impact factor: 5.226

5. Antibodies to core lipopolysaccharide determinants: absence of cross-reactivity with heterologous lipopolysaccharides.

Authors: D Heumann; J D Baumgartner; H Jacot-Guillarmod; M P Glauser
Journal: J Infect Dis Date: 1991-04 Impact factor: 5.226

6. Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial.

Authors: I Schedel; U Dreikhausen; B Nentwig; M Höckenschnieder; D Rauthmann; S Balikcioglu; R Coldewey; H Deicher
Journal: Crit Care Med Date: 1991-09 Impact factor: 7.598

7. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Authors: E J Ziegler; C J Fisher; C L Sprung; R C Straube; J C Sadoff; G E Foulke; C H Wortel; M P Fink; R P Dellinger; N N Teng
Journal: N Engl J Med Date: 1991-02-14 Impact factor: 91.245

8. Endotoxemia in human septic shock.

Authors: R L Danner; R J Elin; J M Hosseini; R A Wesley; J M Reilly; J E Parillo
Journal: Chest Date: 1991-01 Impact factor: 9.410

9. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.

Authors: R L Greenman; R M Schein; M A Martin; R P Wenzel; N R MacIntyre; G Emmanuel; H Chmel; R B Kohler; M McCarthy; J Plouffe
Journal: JAMA Date: 1991-08-28 Impact factor: 56.272

10. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies.

Authors: J D Baumgartner; D Heumann; J Gerain; P Weinbreck; G E Grau; M P Glauser
Journal: J Exp Med Date: 1990-03-01 Impact factor: 14.307

10 in total

Review 8. Principles of antibody therapy.

Authors: S J Russell; M B Llewelyn; R E Hawkins
Journal: BMJ Date: 1992-12-05

Review 9. Neutrophil-mediated tissue injury and its modulation.

Authors: S Fujishima; N Aikawa
Journal: Intensive Care Med Date: 1995-03 Impact factor: 17.440

Review 10. Therapeutic applications of monoclonal antibodies.

Authors: Mitchell Berger; Vidya Shankar; Abbas Vafai
Journal: Am J Med Sci Date: 2002-07 Impact factor: 2.378

10 in total

Monoclonal antibodies in sepsis and septic shock.

1. Anonymised screening for HIV: first results.

2. Monoclonal antibodies to endotoxin. New allies against sepsis?

3. Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome.

4. Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5.

5. Antibodies to core lipopolysaccharide determinants: absence of cross-reactivity with heterologous lipopolysaccharides.

6. Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial.

7. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

8. Endotoxemia in human septic shock.

9. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.

10. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies.

1. Treatment of sepsis with activated protein C.

Review 2. Back to the future: antibody-based strategies for the treatment of infectious diseases.

Review 3. The pulmonary physician and critical care. 3. Pharmacotherapy in lung injury.

4. Monoclonal antibodies in sepsis and septic shock.

5. Monoclonal antibodies in sepsis.

Review 6. The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin.

7. The cost of intensive care: a comparison on one unit between 1988 and 1991.

Review 8. Principles of antibody therapy.

Review 9. Neutrophil-mediated tissue injury and its modulation.

Review 10. Therapeutic applications of monoclonal antibodies.